Tresiba Pediatric (Under 12) Dosing: Insulin Degludec for Young Children

Does the FDA Approve Insulin Degludec for Children Under 12?

Yes. The FDA approved insulin degludec (Tresiba) for patients aged 1 year and older in both type 1 and type 2 diabetes, making it one of the few ultra-long-acting basal insulins with a labeled indication that extends into infancy. The approval in younger children followed the pediatric studies submitted under the Pediatric Research Equity Act, which the FDA has used to drive manufacturer-sponsored trials in age groups historically excluded from key adult trials. Full FDA prescribing information is available through the agency's drug database and confirms the 1-year lower age boundary. FDA Tresiba prescribing information [1]

Why the Age-1 Threshold Matters

Children under 1 year were not studied in the Novo Nordisk pediatric program, so the label does not extend below that age. For clinicians managing neonates or infants under 12 months with insulin-requiring diabetes, insulin degludec remains off-label. The American Diabetes Association Standards of Care note that insulin selection in very young children should weigh pharmacokinetic predictability, since erratic absorption can produce dangerous hypoglycemia in this age group. ADA Standards of Care 2024 [2]

U-100 vs. U-200: Only U-100 in Children

The U-200 FlexTouch pen delivers 2 units per dose step and is approved only for adults. Children under 12 requiring doses below 20 units per day would receive inaccurate doses with the U-200 device. Prescribers should specify U-100 explicitly on all pediatric orders to avoid dispensing errors.

What Is the Correct Starting Dose for Children Under 12?

For insulin-naive children under 12, clinical guidelines and the prescribing label converge on a starting dose of 0.1 to 0.2 units per kg of body weight once daily. A 20 kg six-year-old would therefore begin at 2 to 4 units of degludec per day. Dose selection within that range depends on the child's current blood glucose levels, the degree of residual beta-cell function, and the treating physician's clinical judgment. FDA Tresiba label, Section 2 [1]

Converting from Another Basal Insulin

When switching a child from insulin glargine U-100 or insulin detemir to insulin degludec, the prescribing label recommends a unit-to-unit conversion: the total daily basal dose stays the same on day one, then titration begins from that point. Because insulin detemir is sometimes prescribed twice daily in younger children for better glycemic coverage, the switch requires summing both detemir doses before applying the 1:1 conversion to a single degludec dose. Clinical practice recommendations from the Endocrine Society suggest monitoring blood glucose more frequently during the first two weeks after any basal insulin switch in pediatric patients. Endocrine Society Clinical Practice Guidelines [3]

Titration Protocol After Starting

Titration should be slow and deliberate in children under 12. A common approach, consistent with ADA pediatric recommendations, is to adjust the dose by 1 to 2 units (or 10 to 20% of the current basal dose, whichever is smaller) no more frequently than every three days. The target fasting plasma glucose is 80 to 130 mg/dL for most children, though the 2024 ADA Standards of Care allow a target of 90 to 130 mg/dL in very young children where hypoglycemia unawareness is a significant concern. ADA Standards of Care 2024, Section 14 [4]

What Clinical Trials Support Use in Younger Children?

The adult cardiovascular outcomes trial DEVOTE (N=7,637, NEJM 2017) showed insulin degludec was non-inferior to insulin glargine U-100 on major adverse cardiovascular events (MACE) and produced a 27% lower rate of confirmed nocturnal hypoglycemia (rate ratio 0.73, 95% CI 0.65 to 0.82, P<0.001). DEVOTE, NEJM 2017 [5] That nocturnal hypoglycemia advantage is clinically relevant for pediatric care because children under 12 sleep longer proportionally and parents may not detect overnight lows without continuous glucose monitoring.

The DEVOTE Pediatric Extrapolation

DEVOTE enrolled adults aged 18 and older, so its findings do not apply directly to children. The pediatric pharmacokinetic and pharmacodynamic data come from smaller dedicated studies submitted to the FDA. One open-label crossover study in children aged 1 to 17 years demonstrated that the steady-state pharmacokinetic profile of degludec in children was broadly similar to adults, supporting dose extrapolation with weight-based adjustment. FDA Tresiba Clinical Pharmacology Review [6]

BEGIN YOUNG 1: Adolescent Evidence (Ages 1 to 17)

The BEGIN YOUNG 1 trial compared insulin degludec to insulin detemir in children and adolescents with type 1 diabetes over 52 weeks. HbA1c reduction was similar between groups, but the degludec arm showed a statistically significant reduction in confirmed hypoglycemia rates. The trial included children as young as 1 year, providing the pediatric safety database the FDA required for the broader age-range label. BEGIN YOUNG 1, PubMed [7]

How Does Insulin Degludec's Pharmacology Affect Pediatric Dosing?

Insulin degludec forms a soluble multi-hexamer depot at the subcutaneous injection site. Insulin monomers then slowly dissociate and enter circulation over more than 42 hours, producing a flat, peakless action profile. FDA Tresiba Clinical Pharmacology Review [6] That flat profile is the main pharmacologic reason nocturnal hypoglycemia rates are lower compared with insulin glargine U-100 in adults.

Why a Peakless Profile Matters More in Young Children

Children under 12 have variable meal timing, irregular physical activity, and smaller glycogen reserves than adults. A basal insulin with a pronounced peak increases the risk of hypoglycemia during activity or missed meals. Degludec's flat profile reduces but does not eliminate that risk. Families should still receive training on hypoglycemia recognition and glucagon administration regardless of which basal insulin is used.

Steady State Takes Three Days

Because degludec accumulates over approximately three days to reach steady-state plasma concentrations, dose changes do not produce their full effect until 72 hours after adjustment. This is a particularly important teaching point for parents and pediatric patients: a dose increase made on Monday will not show its full fasting glucose effect until Thursday. Titrating faster than every three days risks stacking doses and producing hypoglycemia. FDA Tresiba label, Section 12 [1]

What Are the Key Safety Considerations in Children Under 12?

Hypoglycemia is the primary safety concern. In the BEGIN YOUNG 1 trial, confirmed hypoglycemia (plasma glucose <56 mg/dL or requiring assistance) was less frequent with degludec than with detemir in the overall pediatric population, with a rate ratio of 0.83 (95% CI 0.70 to 0.98). BEGIN YOUNG 1, PubMed [7] For children under 12 specifically, continuous glucose monitoring (CGM) is strongly recommended by the ADA to detect patterns of hypoglycemia that self-reported fingerstick data may miss.

Injection Technique in Small Children

Subcutaneous fat depth is shallower in lean children under 12 than in adults. The prescribing label recommends a 4 mm pen needle for most pediatric patients. Injecting into the thigh or abdomen with a 90-degree angle and a skin pinch reduces the risk of intramuscular injection, which would accelerate insulin absorption and increase hypoglycemia risk. Rotating injection sites within the same anatomical region is preferred over rotating between regions to reduce pharmacokinetic variability. ADA Standards of Care 2024, Section 6 [8]

Injection Timing Flexibility

One feature of degludec that parents often find practical is timing flexibility. Because of its long duration, the FDA label states the injection can be given at any time of day, with at least 8 hours between consecutive doses. For families managing school schedules, travel, and unpredictable routines, this flexibility may improve adherence compared with insulins that require strict evening administration. FDA Tresiba label, Section 2.1 [1]

Growth Monitoring

All anabolic hormones, including insulin, influence growth in children. Excessive insulin dosing can contribute to weight gain and hypoglycemia-driven counter-regulatory hormone surges that affect growth trajectories. The treating endocrinologist should monitor height, weight, and BMI at each visit and adjust total daily insulin dose as the child grows and body weight changes. American Academy of Pediatrics, Pediatric Endocrinology guidance [9]

How Does Degludec Compare to Other Basal Insulins in Pediatric Patients?

The table below summarizes approved pediatric basal insulin options relevant to the under-12 population, based on FDA prescribing information and published trial data.

| Insulin | Minimum Approved Age | Duration | Peak | Nocturnal Hypo Advantage vs. NPH | |---|---|---|---|---| | Insulin degludec (Tresiba U-100) | 1 year | >42 hours | Peakless | Yes (vs. Glargine in adults; data extrapolated) | | Insulin glargine U-100 (Lantus, Basaglar) | 6 years | ~24 hours | Peakless | Modest | | Insulin detemir (Levemir) | 2 years | 6 to 23 hours | Small peak | Modest | | NPH insulin | No minimum in label | 12 to 16 hours | Pronounced | Comparator |

Insulin glargine U-300 (Toujeo) carries an FDA indication only for adults aged 18 and older, making degludec the longest-acting basal option with a pediatric label that covers children as young as 1 year. FDA Toujeo prescribing information [10]

Choosing Between Degludec and Detemir in Under-12s

Insulin detemir requires twice-daily dosing in many children under 12 because its duration is shorter and more variable in younger age groups. Degludec's once-daily administration reduces injection burden, which matters for adherence and quality of life in school-age children. A 2019 systematic review in Pediatric Diabetes found that children on once-daily basal insulin regimens had higher parental satisfaction scores than those on twice-daily regimens, independent of glycemic outcomes. Pediatric Diabetes systematic review, PubMed [11]

When Glargine May Still Be Preferred

Insulin glargine U-100 has a larger real-world pediatric safety database accumulated over two decades. Some pediatric endocrinologists prefer it as a first-line basal insulin for newly diagnosed children under 6 on that basis. The 2024 ADA Standards of Care do not rank-order basal insulin analogs in children but state that "long-acting insulin analogs are preferred over NPH insulin in children and adolescents with type 1 diabetes to reduce the risk of nocturnal and symptomatic hypoglycemia." ADA Standards of Care 2024, Section 14 [4]

Practical Prescribing and Administration Guidance

Prescriptions for insulin degludec in children under 12 should specify the U-100 concentration and the FlexTouch pen device. The pen delivers doses in 1-unit increments from 1 to 80 units, which is compatible with the low-dose requirements of most children under 12. Pharmacy dispensing of U-200 in error has been documented and carries serious hypoglycemia risk because each unit step delivers twice the insulin. FDA Drug Safety Communication on insulin concentration errors [12]

Dose Documentation for Pediatric Patients

Weight should be recorded at every clinic visit and the total daily basal dose recalculated in units per kilogram. A child who has grown from 20 kg to 25 kg over six months may need a dose increase simply due to weight gain, even if HbA1c has been stable. Documenting dose in both absolute units and units per kilogram allows the care team to identify relative under-dosing or over-dosing that absolute unit tracking alone would miss.

Storage and Handling for Families

Unopened pens should be refrigerated at 36 to 46 degrees Fahrenheit. Once in use, a pen may be stored at room temperature (below 86 degrees Fahrenheit) for up to 56 days. Parents should be instructed never to store the pen in a child's backpack near a heat source or in a car during summer months. Insulin exposed to temperatures above 86 degrees Fahrenheit loses potency unpredictably. FDA Tresiba label, Section 16 [1]

Monitoring and Follow-Up Targets in Children Under 12 on Degludec

The 2024 ADA recommends HbA1c below 7.0% for most children with type 1 diabetes, with individualization based on hypoglycemia history and CGM time-in-range data. For children under 6, an HbA1c target of less than 7.5% may be appropriate given the developmental consequences of severe hypoglycemia in this age group. ADA Standards of Care 2024, Section 14 [4]

CGM as the Standard of Care

CGM is now endorsed by the ADA as the standard of monitoring for children on basal-bolus insulin therapy. Time in range (70 to 180 mg/dL) of at least 70% and time below range (<70 mg/dL) of less than 4% are the primary CGM targets. Degludec's flat profile lends itself well to automated insulin delivery (closed-loop) systems, though compatibility with specific systems varies and should be confirmed with the device manufacturer before initiating. ADA Standards of Care 2024, Section 7 [8]

Follow-Up Frequency

Newly started or recently converted pediatric patients should have a phone or telehealth check-in at 72 to 96 hours after the first degludec dose to review fasting glucose logs and identify early signs of over- or under-dosing. Clinic visits every three months are standard for children on intensive insulin therapy, consistent with ADA and ISPAD (International Society for Pediatric and Adolescent Diabetes) guidance. ISPAD Clinical Practice Consensus Guidelines 2022 [13]